Clinical Trials Sponsored by Cancer Therapeutics Research Group

Total 782 results

Cancer Therapeutics Research Group
National Cancer Institute (NCI)

Completed

Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer

Prostate Cancer

Australia, Singapore, Hong Kong
Cancer Therapeutics Research Group
National Cancer Institute (NCI)

Completed

3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer

Lung Cancer

Australia, Singapore, Hong Kong, Korea, Republic of
Cancer Therapeutics Research Group
National Cancer Institute (NCI)

Completed

Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer

Gastric Cancer

Australia, Singapore, Hong Kong, Korea, Republic of
Cingulate Therapeutics
Premier Research Group plc

Active, not recruiting

Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

ADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit Hyperactivity

United States
Canadian Cancer Trials Group
Repare Therapeutics

Recruiting

RP-6306 in Patients With Advanced Cancer

Advanced Cancer

Canada
Intensity Therapeutics, Inc.
Premier Research Group plc

Not yet recruiting

A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) (INVINCIBLE-3)

Sarcoma,Soft Tissue
Vyne Therapeutics Inc.
Premier Research Group plc

Completed

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Facial Papulopustular Rosacea

United States
Vyne Therapeutics Inc.
Premier Research Group plc

Completed

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Facial Papulopustular Rosacea

United States
Cancer Research Group - Collaborative Group, Beirut...

Unknown

Maintenance Oral Vinorelbine or Observation After Vinorelbine-Docetaxel First Line Chemotherapy in Advanced Breast Ca (TNM)

Breast Cancer

Lebanon
Rare Thyroid Therapeutics International AB
Premier Research Group plc; Egetis Therapeutics

Recruiting

Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency) (ReTRIACt)

Monocarboxylate Transporter 8 Deficiency | Allan-Herndon-Dudley Syndrome

United States, United Kingdom, Netherlands
Gabrail Cancer Center Research
Karyopharm Therapeutics Inc

Completed

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Carcinoma, Neuroendocrine

United States
NCIC Clinical Trials Group
Cascadian Therapeutics Inc.

Completed

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Glioblastoma

Canada
Mateon Therapeutics
Cancer Research UK

Completed

Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

Solid Tumors

United Kingdom
SOLTI Breast Cancer Research Group

Recruiting

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA)

Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-negative Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Terminated

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer (NEREA)

Breast Cancer

Spain, Portugal
Cancer Research UK
Latus Therapeutics

Terminated

A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) (SPIKE-1)

COVID-19 Infection

United Kingdom
SOLTI Breast Cancer Research Group

Not yet recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan (ACROSS-TROP2)

Breast Cancer Stage IV

Spain
SOLTI Breast Cancer Research Group

Recruiting

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (SOLTI-2104)

Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Premenopausal Breast Cancer

Spain
Spanish Breast Cancer Research Group

Recruiting

Registry Study of Pregnancy and Breast Cancer (EMBARCAM)

Breast Cancer and Pregnancy

Spain
SOLTI Breast Cancer Research Group

Completed

Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (PATRICIA II)

Metastatic Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Terminated

Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC (ARIANNA)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Completed

Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer (ONAWA)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Completed

Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer (Opti-HER)

Breast Cancer

Spain
Cancer Research UK
Bicycle Therapeutics

Completed

BT1718 in Patients With Advanced Solid Tumours.

Non-Small Cell Lung Cancer | Advanced Solid Tumours | Oesophageal Cancer | Non-Small Cell Lung Sarcoma

United Kingdom
Spanish Breast Cancer Research Group

Active, not recruiting

Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer (NIKOLE)

Metastatic Breast Cancer

Spain
Spanish Breast Cancer Research Group

Completed

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer (ChangHER-SC)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Completed

SOLTI Breast Cancer Molecular Screening Program (AGATA) (AGATA)

Metastatic Breast Cancer

Spain
Allarity Therapeutics
Danish Breast Cancer Cooperative Group; Smerud Medical Research International...

Active, not recruiting

Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

Metastatic Breast Cancer

Denmark
Larimar Therapeutics, Inc.
Veristat, Inc.; Metrum Research Group, LLC

Completed

Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

Friedreich Ataxia

United States
Larimar Therapeutics, Inc.
Veristat, Inc.; Metrum Research Group, LLC

Completed

Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

Friedreich Ataxia

United States
Swiss Group for Clinical Cancer Research
German Testicular Cancer Study Group

Active, not recruiting

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

Seminoma | Testicular Cancer

Germany, Switzerland
ECOG-ACRIN Cancer Research Group

Not yet recruiting

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

Glioblastoma, IDH-Wildtype
ECOG-ACRIN Cancer Research Group

Recruiting

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Invasive Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
ECOG-ACRIN Cancer Research Group

Recruiting

Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Lymphoblasts 5 Percent or More of Bone Marrow Nucleated Cells

United States
Canadian Cancer Trials Group
Amgen; Canadian Myeloma Research Group

Completed

High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Multiple Myeloma

Canada
Swiss Group for Clinical Cancer Research
Nordic Lymphoma Group

Terminated

Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma

Follicular Lymphoma

Sweden, Finland, Denmark, Norway, Switzerland, Austria
UNICANCER
ARCAGY/ GINECO GROUP; SOLTI Breast Cancer Research Group

Active, not recruiting

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF)

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer | a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status

France
Cancer Research UK
Heptares Therapeutics Limited

Recruiting

HTL0039732 in Participants With Advanced Solid Tumours

Sarcoma | Neoplasms | Kidney Neoplasms | Uterine Cervical Neoplasms | Stomach Neoplasms | Head and Neck Neoplasms | Lung Neoplasms | Urinary Bladder Neoplasms | Colorectal Neoplasms | Pancreatic Neoplasms | Esophageal Neoplasms | Mesothelioma, Malignant | Prostatic Neoplasms, Castration-Resistant | Pheochromocytomas

United Kingdom
Swiss Group for Clinical Cancer Research

Not yet recruiting

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Triple-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma (SAKK 38/23)

Non-hodgkin Lymphoma, B Cell

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Leukemia | Chronic Lymphocytic Leukemia | Relapsed/Refractory Chronic Lymphocytic Leukemia

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Prostate Cancer | Prostate Cancer Metastatic

France, Switzerland, Spain, Italy
Swiss Group for Clinical Cancer Research

Completed

Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients

Lung Cancer

Germany, Serbia, Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

1st Line Durvalumab in PS 2 NSCLC Patients

NSCLC Stage IV | NSCLC Stage IIIB

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Small Cell Lung Cancer | Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. (SAKK 06/17)

Urothelial Cancer

Germany, Switzerland
Spanish Breast Cancer Research Group
Sanofi

Completed

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

Breast Neoplasms

Spain
Spanish Breast Cancer Research Group
Novartis

Completed

Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients (EDALINE)

Advanced Breast Cancer

Spain
Spanish Breast Cancer Research Group
Novartis

Completed

Pamidronate Administration in Breast Cancer Patients With Bone Metastases

Breast Cancer | Neoplasm Metastasis

Spain
Spanish Breast Cancer Research Group
AstraZeneca

Completed

Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETABreast)

Advanced Breast Cancer

Spain

Clinical Trials Sponsored by Cancer Therapeutics Research Group

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations